The injectable data is from rigorous randomized controlled trials
The best part is, theres no downtime
[DOI] [PMC free article] [PubMed] [Google Scholar] 222.Mozaffarian D., Aspry K.E., Garfield K., Kris-Etherton P., Seligman H., Velarde G.P., Williams K., Yang E., et al
Tirzepatide has shown the largest results so far, with average reductions ranging from 15% to nearly 21% over 72 weeks, depending on dose
In fact, patients who experience some initial nausea often show stronger weight loss outcomes because the medication is effectively activating appetite-suppressing pathways
Effectiveness and safety of daily oral semaglutide in people with type 2 diabetes mellitus switching from sulfonylureas: A real-world retrospective study